Company News

Home > Newsroom > Company News Print
CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset


·        The newly founded relationship will combine the researchand development ingenuity ofFapon Biopharma with thestate-of-art biologics manufacturing services offered by CMAB

·        CMAB will provide a full range of development andmanufacturing services for Fapon Biopharma’sbiologic drug project

·        The first in class biologic was independently discovered anddeveloped by Fapon Biopharma and shows significant promise for the treatment ofcancers such as lung, stomach and colorectal cancer

SUZHOU,SHENZHEN, China, November 29, 2019 /PRNewswire/ -- CMAB Biopharma(Suzhou) Inc. (“CMAB”), a pure-play, biologics contract manufacturing anddevelopment organization (CDMO) and Shenzhen Fapon Biopharma Inc. (“FaponBiopharma”), an innovative biopharmaceutical company, announced a comprehensivestrategic agreement for the development and manufacturing of an undisclosed biologicdrug project.

According to theagreement, Fapon Biopharma will avail of the fully integrated CMC processdevelopment and manufacturing platform, the European QP audited product qualitysystem and the experienced regulatory team in dual IND filings in both Chinaand the United States at CMAB.

Quote from Dr. Lisheng Lu, Chief Scientist of Fapon Biopharma:

"Fapon Biotechnology is a leadingsupplier of raw materials and solutions for IVD reagent, which is well-known inthe industry for its leading R&D technology and excellent product quality.

With in-depth understanding of thepharmaceutical industry and strong resource support, Fapon Biopharma wasestablished in 2015. With innovation-driven R&D as the core, our positioningis to develop and produce high-quality innovative biopharmaceuticals to savepatients' lives.

After communication and the on-siteinvestigation, we found that Fapon Biopharma is highly consistent with CMAB. Meetingour core needs, CMAB has a deep understanding of biologic drugs, and canformulate a CMC strategy to help us control risks and ensure that themilestones of each stage can be quickly reached with high quality. "

Quote from Dr. Yongzhong Wang, CEO of CMAB Biopharma:

"We are very excited and proud tobe able to closely participate in this meaningful biologic drug development projectof Fapon Biopharma. The founding aspiration and goal of CMAB is to make ourcustomers successful as quickly as possible. We are willing and confident towork with innovative biopharmaceutical companies such as Fapon Biopharma to overcometechnical difficulties, reduce R&D costs, reach milestones quickly and ofhigh quality, and create sustainable value for customers. "

About Fapon Biopharma Inc.

Fapon Biopharma is a biopharmaceuticalresearch and development enterprise with innovation as its core. It iscommitted to applying cutting-edge new technologies, focusing on thedevelopment and production of new biological drug of monoclonal antibodies andcell therapy products for the treatment of tumors and autoimmune diseases. The core team is composed of senior scientists with experience in the research and development of innovative biological drugs from well-known international pharmaceutical companies. Our goal is to develop high-quality,patient-affordable innovative drugs to save patients' lives.

Fapon Biopharma is located in Songshan Lake Hi-tech Park, Dongguan, Guangdong, a national 4A-level scenic area. It has more than 2000m² R&D laboratory and a more than 2000m² pilot production laboratory under construction. It also has a R&D center in Shanghai with hardware investment of 100 million yuan. Fapon Biopharma has established aninternationally advanced R&D team and a pre-clinical R&D platform for biopharmaceuticals,and has established a rich pipeline of R&D for new biological drugs such asmonoclonal antibodies and fusion proteins. Fapon Biopharma's international vision,high-quality standard requirements, advanced management concepts, and innovation-drivencore values have laid a good foundation for the company's sustainabledevelopment in the future, and provided unlimited personal development andgrowth for employees.

About CMAB Biopharma Inc.

CMAB Biopharma Inc. is a flexiblefull-service CDMO dedicated to providing bespoke development and manufacturingservices of antibodies and biologics for clients in China and across the globe.Our adaptable, service-oriented business enables clients to take theirinnovative concepts for tomorrow's medicines from DNA to cGMP product today.

Follow us

Site Map|Privacy Policy|Terms of Use|Contact

Copyright © 2018 CMAB BioPharma (Suzhou) Inc.   苏ICP备18005502号